Quantcast
Home > Quotes > EOLS

Evolus, Inc. Common Stock (EOLS) Quote & Summary Data

EOLS 
$14.8
*  
0.06
0.41%
Get EOLS Alerts
*Delayed - data as of Nov. 16, 2018  -  Find a broker to begin trading EOLS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    EOLS Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 15.4557 / $ 14.36
Share Volume
417,263
50 Day Avg. Daily Volume
346,200
Previous Close
$ 14.74
52 Week High / Low
$ 39.50 / $ 6.75
Market Cap
403,669,867
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
417,263
50 Day Avg. Daily Volume:
346,200

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.23

Trading Range

The current last sale of $14.80 is 119.26% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 15.4557 $ 39.50
 Low: $ 14.36 $ 6.75

Company Description (as filed with the SEC)

We are a medical aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers. We focus on the self-pay aesthetic market and our first product candidate, PrabotulinumtoxinA (DWP-450) is an injectable 900 kDa botulinum toxin type A complex designed to address the needs of the large and growing facial aesthetics market. We believe we will offer physicians and consumers a compelling value proposition with DWP-450. Currently, onabotulinumtoxinA (BOTOX) is the neurotoxin market leader and the only known approved 900 kDa botulinum toxin type A complex in the United States. We believe aesthetic physicians generally prefer the performance characteristics of the complete 900 kDa neurotoxin complex and are accustomed to injecting this formulation.  ... More ...  


Risk Grade

Where does EOLS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 14.74
Open Date:
Nov. 16, 2018
Close Price:
$ 14.74
Close Date:
Nov. 16, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x